New Horizon Health raises USD20m in Series D round

China’s early-stage cancer screening biotech company New Horizon Health announced that it has raised 20 million US dollars in a Series D financing round, led by private equity fund Omniscience. American Exome Asset Management, and existing investor Qiming Venture Partners, SBCVC and Duke Management Company also participated in the round.

China’s early-stage cancer screening biotech company New Horizon Health announced that it has raised 20 million US dollars in a Series D financing round, led by private equity fund Omniscience. American Exome Asset Management, and existing investors Qiming Venture Partners, SBCVC and Duke Management Company also participated in the round.

Zhu Yeqing, co-founder and CEO of New Horizon Health will be used for the development of new product portfolio, large-scale clinical research investment, service system upgrades and brand building.

Founded in 2013, New Horizon Health has set medical testing laboratories in Beijing, Hangzhou, and Guangzhou. It has launched at-home cancer screening products for intestinal cancer, cervical cancer, gastric cancer and lung cancer, serving more than three million customers. These products allow users to sample at home to discover signs of cancer, and therefore improve the chance of full recovery via simple treatment.

Up to now, New Horizon Health has accumulated more than 130 million US dollars in financing, making it the company that has received the most investment so far in the field of early screening of cancer in China.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/04/26/new-horizon-health-raises-usd20m-in-series-d-round/.

Leave a Reply

Please Login to Comment